The silent crisis pathway: insulin pump infusion failure to pediatric diabetic ketoacidosis — no long-acting depot means no safety buffer
Insulin pumps deliver rapid-acting insulin through a thin subcutaneous cannula, replaced every 2-3 days. The pump's occlusion sensor detects pressure buildup in the tubing — but it cannot detect whether insulin is actually being absorbed into tissue. A kinked cannula tip, a small air bubble in the line, scar tissue at the site, or a cannula that has backed partway out of the skin can all silently stop subcutaneous delivery while the pump continues to display normal operation and count down normal basal rates.
A pump's occlusion detector watches plunger pressure inside the reservoir — a purely mechanical measurement. It can catch a fully blocked line (pressure spikes as the motor pushes against resistance), but many real-world failures do not raise pressure enough to trip the alarm:
• Partial kink: the cannula bends at the skin entry point, allowing some but not all insulin through — pressure rises only slightly • Air bubble: compresses under plunger pressure and absorbs the pump's push before insulin reaches tissue — no resistance signal at all • Site failure (lipohypertrophy, scar tissue): insulin is delivered into fibrotic tissue with poor blood supply, so it pools instead of absorbing — pressure reads completely normal • Dislodgement: cannula partially backs out of skin, delivering insulin into clothing or the adhesive pad rather than tissue
In every one of these cases, the pump's display continues to show "delivering," basal and bolus history logs continue to record doses as given, and no alarm fires — because the sensor is confirming the syringe moved, not that the drug reached the bloodstream.
The single most dangerous property of a silent occlusion is that it produces no distinguishing signal until the downstream consequence — rising glucose — becomes large enough to notice. By the time a child or caregiver sees an unexpectedly high number, the insulin gap may already be hours old.
Infusion-set failure is not one problem but a family of related mechanical faults, each with a different signature:
• Kinked cannula: soft Teflon cannulas can fold at the point of insertion, especially with rapid movement, sports, or sleeping directly on the site — steel cannulas resist kinking but bring higher pain and site-reaction risk • Occlusion from insulin crystallization: insulin can precipitate inside the tubing after 2-3 days at body temperature, gradually narrowing the lumen • Air in the line: introduced during reservoir filling or priming, air is compressible and silently "absorbs" a portion of every bolus • Adhesive failure: heat, sweat, or swimming can loosen the adhesive pad, allowing the cannula to migrate out of the dermis • Lipohypertrophy: repeated insertions in the same small area build fibrous, poorly vascularized tissue that cannot absorb insulin efficiently even with the cannula fully seated
Multiple daily injection regimens combine rapid-acting insulin with a long-acting basal analog (glargine, detemir, degludec) that persists in tissue for 12-42 hours, providing a buffer if a single dose is missed. Insulin pumps abandon that buffer entirely: 100% of delivered insulin is rapid-acting, continuously micro-dosed, with a functional half-life of roughly 4 hours. When delivery stops, the buffer stops with it — and the child is, in effect, insulin-free within a few hours.
Insulin's central job is to suppress lipolysis and hepatic glucose output. When circulating insulin falls below the threshold needed for that suppression, a fast and self-reinforcing cascade begins:
1. Lipolysis accelerates: fat cells release free fatty acids into circulation, unopposed by insulin 2. Hepatic ketogenesis: the liver converts free fatty acids into ketone bodies (beta-hydroxybutyrate, acetoacetate) as an alternative fuel source 3. Counter-regulatory hormones surge: glucagon, cortisol, and catecholamines rise in response to perceived cellular starvation, further driving hepatic glucose release even as blood glucose is already elevated 4. Osmotic diuresis begins: glucose spilling into urine drags water and electrolytes with it, starting the dehydration and electrolyte disturbance that defines DKA 5. Metabolic acidosis develops: ketone bodies are acidic; as they accumulate faster than they can be buffered or excreted, blood pH begins to fall
Because a pump provides no depot insulin, this entire chain can begin within 2 hours of a silent occlusion and become clinically significant DKA within 4-6 hours — a timeline dramatically compressed compared to a basal-bolus injection regimen, where residual long-acting insulin continues suppressing ketogenesis even after a missed rapid-acting dose.
A child on multiple daily injections who misses one rapid-acting dose is still protected by 12-42 hours of background basal insulin. A child on a pump with a silent occlusion has no such protection — the insulin deficit is total from the moment absorption stops, making pump-associated DKA one of the fastest-progressing preventable pediatric endocrine emergencies.
Pediatric patients are disproportionately vulnerable to rapid DKA progression for several physiologic reasons:
• Higher metabolic rate and lower glycogen reserve accelerate the shift toward fat metabolism and ketogenesis • Smaller total body water means a given fluid/electrolyte shift has a proportionally larger effect • Younger children may be unable to verbally communicate early symptoms (nausea, fatigue, thirst), delaying recognition • The developing brain is more susceptible to the cerebral edema that can complicate DKA treatment, particularly with overly rapid correction of glucose or fluid status
These factors are why pediatric DKA protocols diverge meaningfully from adult protocols, especially around fluid resuscitation rate and glucose correction pace.
As ketosis deepens into ketoacidosis, the body's compensatory mechanisms produce a recognizable, escalating symptom pattern. Recognizing this pattern early — ideally through proactive ketone testing rather than waiting for symptoms — is the single highest-leverage intervention point in the entire failure pathway, because every hour of delay compounds dehydration, electrolyte loss, and acidosis.
Symptoms of evolving DKA tend to appear in a roughly predictable order, though pediatric presentation can compress this timeline dramatically:
• Early: increased thirst, frequent urination, fatigue, mild headache — easy to attribute to a bad day, heat, or growth • Gastrointestinal: nausea, vomiting, diffuse abdominal pain — often mistaken for a stomach bug, which is one of the most dangerous misdiagnoses in pump-related DKA because it can delay recognition of the underlying cause • Respiratory compensation: as metabolic acidosis deepens, the body attempts to blow off CO2 through deep, rapid Kussmaul respirations — visible as labored, sighing breaths • Neurological: as acidosis and dehydration progress, lethargy, confusion, and in severe cases decreased consciousness can develop — these are red-flag signs requiring immediate emergency care • Fruity/acetone breath odor: volatile ketone bodies are exhaled directly and are often the most specific single sign to caregivers familiar with the smell
Nausea, vomiting, and abdominal pain from DKA are frequently indistinguishable from a viral gastrointestinal illness at first glance — but the underlying cause and correct response are completely different. A child with a stomach bug and a functioning pump does not need aggressive ketone monitoring. A child with a stomach bug caused by DKA absolutely does, and continuing to trust a pump that is silently failing while treating "just a virus" allows the underlying insulin deficit to keep worsening unchecked.
The distinguishing test is simple and fast: check blood or urine ketones. Any pump user with unexplained hyperglycemia, vomiting, or abdominal pain should have ketones checked before assuming a benign illness — a habit formalized in the "2-hour rule" covered in Stage 5.
Pediatric DKA can progress from mild symptoms to cerebral edema in a matter of hours, faster than the typical adult trajectory. Any pediatric pump user with vomiting, abdominal pain, or lethargy alongside high glucose should be treated as a DKA emergency until proven otherwise by a ketone check.
The moment unexplained hyperglycemia with elevated ketones is identified on pump therapy, a well-defined emergency protocol takes over. The core principle is simple and non-negotiable: the pump is now a suspect device, not a trusted delivery system, and correction insulin must never be routed back through the same equipment that may have caused the problem.
1. Disconnect the pump: stop relying on a delivery system that may be the cause of the problem. Do not attempt another bolus through the same set to "test" it.
2. Check ketones immediately: blood beta-hydroxybutyrate testing is faster and more accurate than urine ketone strips for real-time decision-making, though urine strips remain a reasonable fallback.
3. Give a correction dose by injection: using an insulin pen or vial-and-syringe, administer a weight-appropriate correction dose of rapid-acting insulin subcutaneously — bypassing the pump and any potentially compromised cannula entirely.
4. Replace the entire infusion set: cannula, tubing, and reservoir should all be replaced with fresh components at a new site, since the specific failure point is often not identifiable at the bedside.
5. Recheck glucose and ketones on a schedule: typically every 2-3 hours until both are trending down, confirming the new delivery path is working and the correction is taking effect.
6. Begin cautious fluid resuscitation per pediatric DKA protocol: isotonic fluids given gradually rather than as a rapid bolus, since overly aggressive fluid or glucose correction is a recognized risk factor for cerebral edema in children.
7. Escalate to emergency care when indicated: for significant acidosis, persistent vomiting, altered mental status, or inability to keep the child hydrated orally.
Pediatric DKA fluid and insulin correction protocols intentionally move more slowly than adult protocols. Rapid shifts in osmolality — from either fast fluid boluses or overly aggressive glucose lowering — are strongly associated with cerebral edema in children, so "slow and steady" is a clinical requirement, not overcaution.
It is tempting, in the moment, to simply issue a large correction bolus through the pump and see if the numbers come down. This is precisely the wrong response when infusion failure is suspected, for two reasons:
• If the cannula or line is truly occluded, the "correction" insulin will pool at the site or in the tubing exactly like the doses before it — delivering no therapeutic benefit while consuming critical response time • The delay in recognizing that the pump route failed compounds every hour of ongoing insulin deficiency, allowing acidosis to deepen further before an effective route is used
Injection delivers insulin through a fresh needle directly into a new subcutaneous site (or IV in a hospital setting for severe DKA), guaranteeing absorption independent of whatever mechanical fault affected the pump's cannula.
Every pump-failure DKA episode is also a diagnostic opportunity. A structured post-event review identifies the specific mechanical cause where possible, reinforces the behavioral habits that catch the next failure early, and layers additional technology safeguards so that a single silent occlusion can no longer cascade unnoticed for hours.
After any suspected pump failure, a structured review helps identify — and prevent recurrence of — the specific fault:
• Inspect the removed cannula and tubing for visible kinks, bends, or crystallized insulin residue • Review the insertion site for signs of lipohypertrophy, scarring, or inflammation suggesting the site needs rotation • Check the reservoir-fill and priming technique for air bubble introduction • Confirm cannula wear time did not exceed the recommended 48-72 hour window • Review pump alarm and delivery logs with the diabetes care team to see whether any subtle pressure anomalies were logged but not flagged as alarms • Discuss adhesive performance during sports, swimming, or hot weather, and consider additional adhesive overlays if site loss is a recurring issue
The single most protective behavioral habit for pump users is simple and easy to teach: any unexplained blood glucose reading that stays high despite a correction bolus should trigger a ketone check within 2 hours. If ketones are elevated, the family should assume infusion failure until proven otherwise and move directly into the sick-day protocol — checking the site, considering an injected correction, and not waiting for additional symptoms to appear.
This rule closes the exact gap that makes pump-failure DKA so dangerous: it removes the reliance on the pump's own alarm system (which, as Stage 1 showed, cannot reliably detect subcutaneous failure) and replaces it with a direct physiological check that cannot be silently fooled by a working plunger and a failed cannula.
Teaching families "2 hours of unexplained high glucose = check ketones, don't just re-bolus and wait" is one of the highest-leverage single interventions in pediatric pump safety — it converts a silent failure mode into an actionable, time-bound decision point.
Modern diabetes technology adds further layers of protection on top of behavioral rules:
• Integrated CGM + pump systems: continuous glucose monitors provide trend arrows and high-glucose alerts independent of the pump's own occlusion sensor, offering an orthogonal detection path that does not share the pump's blind spot • Predictive low/high alerts: some systems can flag an abnormal upward trend before glucose reaches a critical threshold, buying extra response time • Automated insulin delivery (hybrid closed-loop) systems: can partially compensate for small delivery gaps by increasing basal rates in response to rising CGM trends, though they cannot fully substitute for a completely occluded cannula • Backup injection supplies: every pump user should carry a rapid-acting insulin pen or vial-and-syringe at all times, precisely so that a correction dose is never delayed by having to source an alternate delivery method during an emergency
None of these tools replace vigilance — but together with the 2-hour rule, they shrink the silent window in Stage 1 from hours to minutes.